Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins?

Area of Science:

• Pharmacology
• Nephrology
• Infectious Diseases

Background:

• Polymyxins (colistin, polymyxin B) are critical last-resort antibiotics against multidrug-resistant Gram-negative bacteria.
• Their use is limited by significant dose-dependent nephrotoxicity, affecting over 50% of patients.
• Optimizing polymyxin use to balance efficacy and minimize kidney toxicity is crucial.

Purpose of the Study:

• To review risk factors associated with polymyxin-induced nephrotoxicity.
• To discuss strategies for mitigating polymyxin-related kidney damage.
• To identify knowledge gaps and future research directions in polymyxin nephrotoxicity.

Main Methods:

• Literature review focusing on polymyxin nephrotoxicity.
• Analysis of risk factors and protective strategies.
• Synthesis of current knowledge and future research needs.

Main Results:

• Nephrotoxicity is a major dose-dependent limitation of polymyxin therapy.
• Several risk factors contribute to polymyxin-associated kidney injury.
• Various strategies exist to potentially reduce nephrotoxicity, though further research is needed.

Conclusions:

• Polymyxins remain essential for treating challenging Gram-negative infections.
• Understanding and managing nephrotoxicity is key to preserving polymyxin utility.
• Further research is required to optimize polymyxin dosing and minimize renal adverse events.